Geron Corporation And TA Therapeutics, Limited Announce Presentation Of New Data Supporting Utility Of Their Small Molecule Telomerase Activator TAT0002
Published: May 15, 2006
MENLO PARK, Calif.--(BUSINESS WIRE)--May 15, 2006--Geron Corporation (Nasdaq:GERN - News) and TA Therapeutics, Ltd., a joint venture between Geron Corporation and the Biotechnology Research Corporation of Hong Kong (BRC), announced today the presentation of studies demonstrating that their small molecule telomerase activator, TAT0002, enhances the anti-viral activity of CD8 T-cells from HIV/AIDS donors against infected CD4 cells from the same donors. TA Therapeutics is exploring multiple applications for telomerase activators in chronic degenerative and infectious diseases. The company's most advanced program is HIV/AIDS, and it has selected TAT0002 as the lead development candidate for this indication.